Anzeige
Meldung des Tages: Diese Goldaktie startet NI-43-101 Ressourcenschätzung – jetzt kann aus der Story Substanz werden

Amicus Therapeutics Aktie News

Aktie
WKN:  A0MSMZ ISIN:  US03152W1099 US-Symbol:  FOLD Branche:  Biotechnologie Land:  USA
11,90 €
+0,00 €
0,00%
07:30:56 Uhr
Depot/Watchlist
Marktkapitalisierung *
3,73 Mrd. €
Streubesitz
-
KGV
37,66
neu: Nachhaltigkeits-Score
37 %
Index-Zuordnung
-

Amicus Therapeutics News

08.01.26 - PR Newswire
Halper Sadeh LLC Encourages THS, FOLD, REVG Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages THS, FOLD, REVG Shareholders to Contact the Firm to Discuss Their Rights PR Newswire
07.01.26 - PR Newswire
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger--EKSO, FOLD, CWAN, and JHG
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger--EKSO, FOLD, CWAN, and JHG PR Newswire
06.01.26 - PR Newswire
Halper Sadeh LLC Encourages DBRG, FOLD, DVAX Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages DBRG, FOLD, DVAX Shareholders to Contact the Firm to Discuss Their Rights PR Newswire
30.12.25 - PR Newswire
Halper Sadeh LLC Encourages EKSO, FOLD, WBD, CFLT Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages EKSO, FOLD, WBD, CFLT Shareholders to Contact the Firm to Discuss Their Rights PR Newswire
23.12.25 - PR Newswire
Halper Sadeh LLC Encourages KPLT, FOLD, DHIL Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages KPLT, FOLD, DHIL Shareholders to Contact the Firm to Discuss Their Rights PR Newswire
19.12.25 - PR Newswire
Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders
Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders PR Newswire
19.12.25 - PR Newswire
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook PR ...
06.08.25 - PR Newswire
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators PR Newswire
06.08.25 - PR Newswire
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators PR Newswire
10.07.25 - PR Newswire
SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term FOLD Investors to Contact the Firm
SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term FOLD Investors to ...

Newssuche

Videos

newspaper
27.01.26 +1,29%
Technical Trading: Pfund Short
GBP/USD Short Typ: Turbo Open End WKN: VH3A2E Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »